PROFIT AND LOSS | 9M 2019 | 9M 2018 | Growth as reported | Growth at CER* |
DKK million | ||||
Net sales | 89,604 | 82,099 | 9% | 5% |
Operating profit | 40,610 | 36,465 | 11% | 5% |
Net profit | 30,234 | 30,131 | 0% | N/A |
Diluted earnings per share (in DKK) | 12.68 | 12.40 | 2% | N/A |
* CER: Constant exchange rates (average 2018)
Lars Fruergaard Jørgensen, president and CEO: "We are very satisfied with the sales growth for the first nine months of 2019, which was driven by all regions in International Operations and growth across our therapy areas Diabetes, Obesity and Biopharmaceuticals. During the third quarter of 2019, we have reached two very important milestones: the US FDA approval of Rybelsus® and the blockbuster status of Ozempic® following the successful launch in the USA; two major events that emphasise the strength of our current and future GLP-1 franchise.”
On 1 November 2019 at 13.00 CET, corresponding to 8.00 am EDT, a conference call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’.
Financial calendar | |
20 November 2019 | Capital Markets Day |
05 February 2020 | Financial statement for 2019 |
Contacts for further information | ||
Media: | ||
Mette Kruse Danielsen | +45 4442 3883 | mkd@novonordisk.com |
Ken Inchausti (USA) | +1 609 240 9429 | kiau@novonordisk.com |
Investors: | ||
Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com |
Valdemar Borum Svarrer | +45 3079 0301 | jvls@novonordisk.com |
Ann Søndermølle Rendbæk | +45 3075 2253 | arnd@novonordisk.com |
Mark Joseph Root | +45 3079 4211 | mjhr@novonordisk.com |
Kristoffer Due Berg (USA) | +1 609 235 2989 | krdb@novonordisk.com |
Company announcement No 62 / 2019
Attachment